Zacks: Analysts Expect Protagonist Therapeutics Inc (PTGX) Will Post Earnings of -$0.65 Per Share
Analysts forecast that Protagonist Therapeutics Inc (NASDAQ:PTGX) will report earnings of ($0.65) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Protagonist Therapeutics’ earnings, with estimates ranging from ($0.70) to ($0.59). Protagonist Therapeutics reported earnings of ($0.36) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 80.6%. The company is expected to announce its next earnings results on Wednesday, May 8th.
According to Zacks, analysts expect that Protagonist Therapeutics will report full year earnings of ($2.77) per share for the current financial year, with EPS estimates ranging from ($3.06) to ($2.47). For the next fiscal year, analysts expect that the business will post earnings of ($2.86) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Protagonist Therapeutics.
Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings data on Tuesday, March 12th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.15). The company had revenue of $2.35 million during the quarter, compared to analyst estimates of $5.45 million. Protagonist Therapeutics had a negative net margin of 125.87% and a negative return on equity of 33.94%.
In other Protagonist Therapeutics news, insider David Y. Liu sold 3,821 shares of the firm’s stock in a transaction on Wednesday, February 6th. The stock was sold at an average price of $7.74, for a total value of $29,574.54. Following the sale, the insider now directly owns 37,007 shares in the company, valued at $286,434.18. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Dinesh V. Ph D. Patel sold 10,909 shares of the firm’s stock in a transaction on Wednesday, February 6th. The shares were sold at an average price of $7.74, for a total value of $84,435.66. Following the completion of the sale, the chief executive officer now owns 367,396 shares in the company, valued at $2,843,645.04. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 17,570 shares of company stock worth $136,815. 13.80% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of PTGX. D. E. Shaw & Co. Inc. increased its position in shares of Protagonist Therapeutics by 75.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 19,645 shares of the company’s stock worth $132,000 after purchasing an additional 8,450 shares in the last quarter. Bank of America Corp DE increased its position in shares of Protagonist Therapeutics by 94.3% during the fourth quarter. Bank of America Corp DE now owns 26,419 shares of the company’s stock worth $178,000 after purchasing an additional 12,819 shares in the last quarter. Northern Trust Corp increased its position in shares of Protagonist Therapeutics by 17.2% during the fourth quarter. Northern Trust Corp now owns 34,624 shares of the company’s stock worth $234,000 after purchasing an additional 5,084 shares in the last quarter. Tibra Equities Europe Ltd acquired a new stake in shares of Protagonist Therapeutics during the first quarter worth about $410,000. Finally, Barclays PLC acquired a new stake in shares of Protagonist Therapeutics during the fourth quarter worth about $462,000. Institutional investors own 59.51% of the company’s stock.
Shares of NASDAQ PTGX opened at $10.47 on Wednesday. The firm has a market capitalization of $244.44 million, a PE ratio of -6.02 and a beta of 2.19. Protagonist Therapeutics has a 12-month low of $5.49 and a 12-month high of $14.36.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis.
Featured Article: Range Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.